Ads
related to: illumina high throughput sequencing in microbiome research
Search results
Results From The WOW.Com Content Network
QIIME (English: / tʃ aɪ m / ch-eye-m) [1] is a bioinformatics data science platform, originally developed for analysis of high-throughput microbiome marker gene (e.g., 16S or 18S rRNA genes) amplicon sequencing data. There have been two major versions of the QIIME platform, QIIME 1 [2] and QIIME 2. [3]
The Sequence Read Archive (SRA, previously known as the Short Read Archive) is a bioinformatics database that provides a public repository for DNA sequencing data, especially the "short reads" generated by high-throughput sequencing, which are typically less than 1,000 base pairs in length. [1]
An amplicon sequence variant (ASV) is any one of the inferred single DNA sequences recovered from a high-throughput analysis of marker genes. Because these analyses, also called "amplicon reads," are created following the removal of erroneous sequences generated during PCR and sequencing, using ASVs makes it possible to distinguish sequence ...
In a separate partnership with Broad Institute and Harvard, San Diego-based Illumina will work on research sequencing of single cells and conduct experiments using technology from the company's ...
Any platform that can allow for the ligated fragments to be sequenced across the NheI junction (Roche 454) or by paired-end or mate-paired reads (Illumina GA and HiSeq platforms) would be suitable for Hi-C. [4] Before high-throughput sequencing, the quality of the library should be verified using Sanger sequencing, wherein the long sequencing ...
Illumina sells a number of high-throughput DNA sequencing systems, also known as DNA sequencers, based on technology developed by Solexa. The technology features bridge amplification to generate clusters and reversible terminators for sequence determination.
The sequencing platform to be used is chosen depending on different factors such as laboratory's research objectives, personal experience and skill levels. So far, the Illumina MiSeq system has proven to be the most commonly used platform for infectious disease research, pathogen surveillance, and pathogen discovery in research and public ...
The first of the high-throughput sequencing technologies, massively parallel signature sequencing (or MPSS, also called next generation sequencing), was developed in the 1990s at Lynx Therapeutics, a company founded in 1992 by Sydney Brenner and Sam Eletr. MPSS was a bead-based method that used a complex approach of adapter ligation followed by ...